0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-acting Non-Ergot Dopamine Agonist CV 205-502

Mary Lee Vance, MD; Maurice Lipper, MD; Anne Klibanski, MD; Beverly M. K. Biller, MD; Naguib A. Samaan, MD, PhD; and Mark E. Molitch, MD
[+] Article and Author Information

Grant Support: By the Sandoz Research Institute and in part by General Clinical Research Center USPHS Grant RR-00847 to the University of Virginia.

Requests for Reprints: Mary Lee Vance, MD, Box 511, University of Virginia Health Sciences Center, Charlottesville, VA 22908.

Current Author Addresses: Dr. Vance: Department of Internal Medicine, Box 511, University of Virginia Health Sciences Center, Charlottesville, VA 22908.

Dr. Lipper: Department of Radiology, Box 170, University of Virginia Health Sciences Center, Charlottesville, VA 22908. Drs. Klibanski and Biller: Department of Internal Medicine, Massachusetts General Hospital, Boston, MA 02114.

Dr. Samaan: Department of Internal Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030. Dr. Molitch: Department of Internal Medicine, Northwestern University Medical School, Chicago, IL 60611.


© 1990 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1990;112(9):668-673. doi:10.7326/0003-4819-112-9-668
Text Size: A A A

Study Objective: Evaluation of the effects of an experimental long-acting non-ergot dopamine agonist, CV 205-502, on serum prolactin, tumor size, gonadal function, visual abnormalities, and tolerability in patients with macroprolactinomas. Design: Prospective, unblinded, dose escalation as needed. Setting: Four university medical centers; patients referred for treatment.

Patients: Twenty-six hyperprolactinemic patients (prolactin > 150 µg/L) with a pituitary macroadenoma were treated for 24 weeks with CV 205-502 given once daily.

Measurements and Main Results: Serum prolactin was measured at regular intervals. Prolactin levels decreased in all patients during treatment (mean pretreatment level, 2051.7 ±1077 µg/L [± SE]; 24 weeks, 39.0 ±11.3 µg/L; P = 0.0001); normal prolactin levels were achieved in 15 (58%). Tumor size decreased in 21 of 26 patients and ranged from 6% to 67% (mean, 19.2% ± 3.4%). Onset or return of regular menses occurred in 11 of 15 premenopausal women, accompanied by an increase in estradiol concentrations (pretreatment, 186.5 ± 25.0 pmol/L; on treatment, 690.9 ± 104.3 pmol/L; P = 0.0003). Serum testosterone increased in 6 of 8 men; sexual function improved in 5 of 7 with pretreatment abnormalities. Two patients with reversible visual abnormalities improved within 2 weeks of starting treatment. Side effects occurred in 11 patients and abated over 1 to 2 weeks or after the dose was reduced. There was no evidence of toxicity as indicated by serial serum chemistries, liver function tests, hematologic profiles, thyroxine levels, and electrocardiogram studies.

Conclusions: CV 205-502 reverses hyperprolactinemia and promotes reduction in tumor size with reversal of visual abnormalities and restoration of gonadal function in most patients. This compound will probably be useful in treating prolactinomas.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Pituitary adenomas: an overview. Am Fam Physician 2013;88(5):319-27.
Giant prolactinomas in women. Eur J Endocrinol 2014;170(1):31-8.

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)